ImmuCell Corporation (ICCC)
USD 5.29
(-1.22%)
USD 5.29
(-1.22%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -5.74 Million USD | -150.03% |
| 2022 | -2.29 Million USD | -4.3% |
| 2021 | -2.2 Million USD | -59.72% |
| 2020 | -1.38 Million USD | -44.65% |
| 2019 | -954 Thousand USD | 34.07% |
| 2018 | -1.44 Million USD | -495.47% |
| 2017 | -243 Thousand USD | -127.3% |
| 2016 | 890.2 Thousand USD | -58.06% |
| 2015 | 2.12 Million USD | 1128.27% |
| 2014 | -206.39 Thousand USD | -955.64% |
| 2013 | -19.55 Thousand USD | -107.98% |
| 2012 | 245 Thousand USD | 138.72% |
| 2011 | -632.72 Thousand USD | 8.34% |
| 2010 | -690.28 Thousand USD | -30.98% |
| 2009 | -527.02 Thousand USD | 54.86% |
| 2008 | -1.16 Million USD | -233.88% |
| 2007 | 872.1 Thousand USD | 13.16% |
| 2006 | 770.68 Thousand USD | -17.84% |
| 2005 | 938.03 Thousand USD | 676.7% |
| 2004 | 120.77 Thousand USD | 128.15% |
| 2003 | -429.03 Thousand USD | -180.47% |
| 2002 | 533.14 Thousand USD | -20.55% |
| 2001 | 671 Thousand USD | 62.32% |
| 2000 | 413.37 Thousand USD | -32.78% |
| 1999 | 614.97 Thousand USD | 0.0% |
| 1998 | - USD | -100.0% |
| 1997 | 300 Thousand USD | 400.0% |
| 1996 | -100 Thousand USD | 0.0% |
| 1995 | - USD | 100.0% |
| 1994 | -300 Thousand USD | -200.0% |
| 1993 | -100 Thousand USD | 66.67% |
| 1992 | -300 Thousand USD | 78.57% |
| 1991 | -1.4 Million USD | -180.0% |
| 1990 | -500 Thousand USD | 44.44% |
| 1989 | -900 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -300.05 Thousand USD | 70.08% |
| 2024 Q2 | -1.38 Million USD | -362.13% |
| 2023 Q3 | -1.18 Million USD | 9.23% |
| 2023 FY | -5.74 Million USD | -150.03% |
| 2023 Q2 | -1.3 Million USD | 42.18% |
| 2023 Q1 | -2.25 Million USD | -38.08% |
| 2023 Q4 | -1 Million USD | 15.29% |
| 2022 FY | -2.29 Million USD | -4.3% |
| 2022 Q4 | -1.63 Million USD | -164.8% |
| 2022 Q1 | 792.98 Thousand USD | 446.79% |
| 2022 Q2 | -592.76 Thousand USD | -174.75% |
| 2022 Q3 | -617 Thousand USD | -4.09% |
| 2021 Q4 | 145.02 Thousand USD | -46.5% |
| 2021 Q3 | 271.09 Thousand USD | 25.79% |
| 2021 Q2 | 215.5 Thousand USD | 157.53% |
| 2021 FY | -2.2 Million USD | -59.72% |
| 2021 Q1 | -374.62 Thousand USD | 40.91% |
| 2020 Q2 | -691.26 Thousand USD | -451.12% |
| 2020 Q4 | -634 Thousand USD | -151.99% |
| 2020 FY | -1.38 Million USD | -44.65% |
| 2020 Q3 | -251.59 Thousand USD | 63.6% |
| 2020 Q1 | 196.87 Thousand USD | 181.35% |
| 2019 Q1 | 265.3 Thousand USD | 128.65% |
| 2019 FY | -954 Thousand USD | 34.07% |
| 2019 Q2 | -547 Thousand USD | -306.18% |
| 2019 Q3 | -429.81 Thousand USD | 21.42% |
| 2019 Q4 | -242 Thousand USD | 43.7% |
| 2018 Q4 | -926 Thousand USD | -520.89% |
| 2018 Q3 | -149.14 Thousand USD | 22.89% |
| 2018 Q2 | -193.4 Thousand USD | -8.56% |
| 2018 Q1 | -178.15 Thousand USD | 56.86% |
| 2018 FY | -1.44 Million USD | -495.47% |
| 2017 Q1 | 918.2 Thousand USD | 669.61% |
| 2017 FY | -243 Thousand USD | -127.3% |
| 2017 Q4 | -413 Thousand USD | 14.39% |
| 2017 Q3 | -482.41 Thousand USD | -81.83% |
| 2017 Q2 | -265.3 Thousand USD | -128.89% |
| 2016 Q1 | 698.96 Thousand USD | 51.48% |
| 2016 FY | 890.2 Thousand USD | -58.06% |
| 2016 Q4 | 119.3 Thousand USD | 136.41% |
| 2016 Q3 | 50.46 Thousand USD | 135.11% |
| 2016 Q2 | 21.46 Thousand USD | -96.93% |
| 2015 Q4 | 461.43 Thousand USD | -26.39% |
| 2015 FY | 2.12 Million USD | 1128.27% |
| 2015 Q1 | 820.05 Thousand USD | 312.38% |
| 2015 Q3 | 626.85 Thousand USD | 192.94% |
| 2015 Q2 | 213.98 Thousand USD | -73.91% |
| 2014 Q2 | -458.66 Thousand USD | -3751.52% |
| 2014 FY | -206.39 Thousand USD | -955.64% |
| 2014 Q4 | 198.85 Thousand USD | 386.76% |
| 2014 Q3 | 40.85 Thousand USD | 108.91% |
| 2014 Q1 | 12.56 Thousand USD | 105.98% |
| 2013 Q4 | -209.97 Thousand USD | -31.26% |
| 2013 Q1 | 326.66 Thousand USD | 2513.75% |
| 2013 Q2 | 23.72 Thousand USD | -92.74% |
| 2013 FY | -19.55 Thousand USD | -107.98% |
| 2013 Q3 | -159.96 Thousand USD | -774.34% |
| 2012 FY | 245 Thousand USD | 138.72% |
| 2012 Q4 | 12.49 Thousand USD | 114.51% |
| 2012 Q3 | -86.12 Thousand USD | -330.3% |
| 2012 Q2 | 37.39 Thousand USD | -86.7% |
| 2012 Q1 | 281.23 Thousand USD | 2897.58% |
| 2011 Q2 | -432.86 Thousand USD | -2467.68% |
| 2011 Q1 | -16.85 Thousand USD | 92.44% |
| 2011 Q3 | -192.39 Thousand USD | 55.55% |
| 2011 Q4 | 9382.00 USD | 104.88% |
| 2011 FY | -632.72 Thousand USD | 8.34% |
| 2010 FY | -690.28 Thousand USD | -30.98% |
| 2010 Q1 | -73.96 Thousand USD | 26.09% |
| 2010 Q2 | -46.09 Thousand USD | 37.68% |
| 2010 Q3 | -347.54 Thousand USD | -654.02% |
| 2010 Q4 | -223.09 Thousand USD | 35.81% |
| 2009 Q2 | -315.78 Thousand USD | -335.73% |
| 2009 Q1 | -72.47 Thousand USD | 75.18% |
| 2009 Q4 | -100.07 Thousand USD | -158.58% |
| 2009 FY | -527.02 Thousand USD | 54.86% |
| 2009 Q3 | -38.7 Thousand USD | 87.74% |
| 2008 Q3 | -549.74 Thousand USD | -39.24% |
| 2008 Q4 | -291.99 Thousand USD | 46.88% |
| 2008 FY | -1.16 Million USD | -233.88% |
| 2008 Q1 | 68.97 Thousand USD | 20.54% |
| 2008 Q2 | -394.82 Thousand USD | -672.42% |
| 2007 Q1 | 430.27 Thousand USD | 235.78% |
| 2007 Q2 | -152.68 Thousand USD | -135.48% |
| 2007 Q4 | 57.21 Thousand USD | -89.35% |
| 2007 Q3 | 537.29 Thousand USD | 451.91% |
| 2007 FY | 872.1 Thousand USD | 13.16% |
| 2006 Q2 | -31.68 Thousand USD | -106.94% |
| 2006 Q4 | 128.14 Thousand USD | -41.12% |
| 2006 Q3 | 217.63 Thousand USD | 786.78% |
| 2006 Q1 | 456.59 Thousand USD | 64.37% |
| 2006 FY | 770.68 Thousand USD | -17.84% |
| 2005 Q3 | 143.65 Thousand USD | 38.8% |
| 2005 Q4 | 277.78 Thousand USD | 93.37% |
| 2005 Q2 | 103.49 Thousand USD | -74.95% |
| 2005 FY | 938.03 Thousand USD | 676.7% |
| 2005 Q1 | 413.1 Thousand USD | 1549.8% |
| 2004 FY | 120.77 Thousand USD | 128.15% |
| 2004 Q1 | 279.42 Thousand USD | 229.93% |
| 2004 Q2 | -109.94 Thousand USD | -139.35% |
| 2004 Q3 | -20.21 Thousand USD | 81.61% |
| 2004 Q4 | -28.49 Thousand USD | -40.96% |
| 2003 Q2 | -214.03 Thousand USD | -406.0% |
| 2003 FY | -429.03 Thousand USD | -180.47% |
| 2003 Q4 | -215.04 Thousand USD | -207.68% |
| 2003 Q3 | -69.89 Thousand USD | 67.34% |
| 2003 Q1 | 69.94 Thousand USD | -71.12% |
| 2002 FY | 533.14 Thousand USD | -20.55% |
| 2002 Q4 | 242.16 Thousand USD | 627.97% |
| 2002 Q3 | 33.26 Thousand USD | 208.99% |
| 2002 Q2 | -30.52 Thousand USD | -110.59% |
| 2002 Q1 | 288.22 Thousand USD | -29.66% |
| 2001 Q3 | -85.55 Thousand USD | -150.82% |
| 2001 Q4 | 409.76 Thousand USD | 578.98% |
| 2001 Q2 | 168.34 Thousand USD | -5.66% |
| 2001 Q1 | 178.44 Thousand USD | -38.65% |
| 2001 FY | 671 Thousand USD | 62.32% |
| 2000 FY | 413.37 Thousand USD | -32.78% |
| 2000 Q4 | 290.84 Thousand USD | 404.0% |
| 2000 Q3 | -95.67 Thousand USD | -609.97% |
| 2000 Q2 | 18.76 Thousand USD | -90.59% |
| 2000 Q1 | 199.44 Thousand USD | 73.47% |
| 1999 FY | 614.97 Thousand USD | 0.0% |
| 1999 Q3 | 200 Thousand USD | 0.0% |
| 1999 Q4 | 114.97 Thousand USD | -42.52% |
| 1999 Q1 | 300 Thousand USD | 0.0% |
| 1999 Q2 | - USD | -100.0% |
| 1998 Q1 | 100 Thousand USD | -75.0% |
| 1998 FY | - USD | -100.0% |
| 1998 Q4 | - USD | -100.0% |
| 1998 Q3 | 100 Thousand USD | 0.0% |
| 1998 Q2 | - USD | -100.0% |
| 1997 Q3 | -100 Thousand USD | 50.0% |
| 1997 Q4 | 400 Thousand USD | 500.0% |
| 1997 FY | 300 Thousand USD | 400.0% |
| 1997 Q1 | 200 Thousand USD | -50.0% |
| 1997 Q2 | -200 Thousand USD | -200.0% |
| 1996 FY | -100 Thousand USD | 0.0% |
| 1996 Q4 | 400 Thousand USD | 300.0% |
| 1996 Q3 | -200 Thousand USD | 0.0% |
| 1996 Q2 | -200 Thousand USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| 1995 FY | - USD | 100.0% |
| 1995 Q4 | - USD | 100.0% |
| 1995 Q3 | -100 Thousand USD | 0.0% |
| 1995 Q2 | -100 Thousand USD | -200.0% |
| 1995 Q1 | 100 Thousand USD | 150.0% |
| 1994 Q2 | 100 Thousand USD | 0.0% |
| 1994 Q4 | -200 Thousand USD | -300.0% |
| 1994 FY | -300 Thousand USD | -200.0% |
| 1994 Q1 | 100 Thousand USD | 200.0% |
| 1994 Q3 | 100 Thousand USD | 0.0% |
| 1993 Q3 | - USD | 0.0% |
| 1993 Q4 | -100 Thousand USD | 0.0% |
| 1993 Q2 | - USD | 0.0% |
| 1993 Q1 | - USD | 100.0% |
| 1993 FY | -100 Thousand USD | 66.67% |
| 1992 Q3 | -100 Thousand USD | -200.0% |
| 1992 Q2 | 100 Thousand USD | 200.0% |
| 1992 FY | -300 Thousand USD | 78.57% |
| 1992 Q4 | -100 Thousand USD | 0.0% |
| 1992 Q1 | -100 Thousand USD | 50.0% |
| 1991 Q1 | -500 Thousand USD | -350.0% |
| 1991 FY | -1.4 Million USD | -180.0% |
| 1991 Q4 | -200 Thousand USD | 60.0% |
| 1991 Q3 | -500 Thousand USD | -66.67% |
| 1991 Q2 | -300 Thousand USD | 40.0% |
| 1990 Q1 | -300 Thousand USD | -50.0% |
| 1990 FY | -500 Thousand USD | 44.44% |
| 1990 Q3 | -300 Thousand USD | -200.0% |
| 1990 Q4 | 200 Thousand USD | 166.67% |
| 1990 Q2 | -100 Thousand USD | 66.67% |
| 1989 Q1 | 700 Thousand USD | 0.0% |
| 1989 FY | -900 Thousand USD | 0.0% |
| 1989 Q3 | -100 Thousand USD | 83.33% |
| 1989 Q4 | -200 Thousand USD | -100.0% |
| 1989 Q2 | -600 Thousand USD | -185.71% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -237.2 Million USD | 97.577% |
| Alkermes plc | 414.12 Million USD | 101.388% |
| Agenus Inc. | -159.54 Million USD | 96.397% |
| Aptorum Group Limited | -10.52 Million USD | 45.378% |
| Ardelyx, Inc. | -63.27 Million USD | 90.916% |
| Dyadic International, Inc. | -8.22 Million USD | 30.155% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | -382.221% |
| Lantern Pharma Inc. | -17.87 Million USD | 67.848% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | 71.388% |
| Novavax, Inc. | -566.51 Million USD | 98.985% |
| Janux Therapeutics, Inc. | -72.97 Million USD | 92.124% |
| Pyxis Oncology, Inc. | -82.19 Million USD | 93.007% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | 70.399% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | 45.583% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | 89.18% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 98.489% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 76.352% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | 84.821% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | 95.544% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | 93.15% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 67.227% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | 86.939% |
| Clearside Biomedical, Inc. | -24.84 Million USD | 76.863% |
| C4 Therapeutics, Inc. | -139.03 Million USD | 95.866% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 97.963% |
| AlloVir, Inc. | -181.33 Million USD | 96.83% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 97.196% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 80.354% |
| Bicycle Therapeutics plc | -189.94 Million USD | 96.974% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | 96.654% |
| ChromaDex Corporation | -5.59 Million USD | -2.663% |
| Chimerix, Inc. | -93.06 Million USD | 93.824% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 87.248% |
| Caribou Biosciences, Inc. | -116.05 Million USD | 95.047% |
| CRISPR Therapeutics AG | -222.53 Million USD | 97.417% |
| Precision BioSciences, Inc. | -43.73 Million USD | 86.857% |
| Fate Therapeutics, Inc. | -190.51 Million USD | 96.983% |
| Fortress Biotech, Inc. | -142.34 Million USD | 95.962% |
| Fortress Biotech, Inc. | -142.34 Million USD | 95.962% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | 94.116% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | 95.724% |
| Immix Biopharma, Inc. | -16.14 Million USD | 64.389% |
| Incyte Corporation | 620.52 Million USD | 100.926% |
| Innoviva, Inc. | 176.7 Million USD | 103.253% |
| IO Biotech, Inc. | -91.44 Million USD | 93.714% |
| Jaguar Health, Inc. | -34.29 Million USD | 83.237% |
| Keros Therapeutics, Inc. | -169.94 Million USD | 96.618% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | 148.133% |
| ContextLogic Inc. | -328 Million USD | 98.248% |
| MiMedx Group, Inc. | 37.11 Million USD | 115.487% |
| MEI Pharma, Inc. | 14.54 Million USD | 139.527% |
| NextCure, Inc. | -67.63 Million USD | 91.502% |
| Onconetix, Inc. | -36.03 Million USD | 84.048% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | 86.22% |
| Opthea Limited | -191.84 Million USD | 97.004% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -108.882% |
| Vaxcyte, Inc. | -468.04 Million USD | 98.772% |
| PDS Biotechnology Corporation | -43.04 Million USD | 86.646% |
| Precigen, Inc. | -88.92 Million USD | 93.536% |
| Pharming Group N.V. | -4.87 Million USD | -17.799% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | 96.564% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | 80.683% |
| PureTech Health plc | -146.19 Million USD | 96.068% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | 71.948% |
| Avidity Biosciences, Inc. | -235.59 Million USD | 97.56% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 76.352% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 97.902% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | 80.385% |
| Acelyrin, Inc. | -422.06 Million USD | 98.638% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | -44476.229% |
| Summit Therapeutics Inc. | -89.73 Million USD | 93.594% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | 84.491% |
| Senti Biosciences, Inc. | -92.72 Million USD | 93.801% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | 94.992% |
| Elevation Oncology, Inc. | -45.44 Million USD | 87.352% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | 83.226% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | -45.815% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | -81.786% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | 82.593% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 32.384% |
| Wave Life Sciences Ltd. | -67.99 Million USD | 91.546% |
| Seer, Inc. | -103.46 Million USD | 94.444% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | 91.259% |
| Aadi Bioscience, Inc. | -71.93 Million USD | 92.009% |
| ESSA Pharma Inc. | -32.13 Million USD | 82.112% |
| GlycoMimetics, Inc. | -39.27 Million USD | 85.365% |
| GT Biopharma, Inc. | -13.57 Million USD | 57.66% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | 97.378% |
| Akebia Therapeutics, Inc. | -46.25 Million USD | 87.573% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 106.621% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 89.873% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | 88.84% |
| Alzamend Neuro, Inc. | -9.93 Million USD | 42.159% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 98.86% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | 16.67% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 88.661% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | 97.786% |
| Aptose Biosciences Inc. | -52.35 Million USD | 89.021% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | 60.14% |
| Soligenix, Inc. | -7.69 Million USD | 25.33% |
| Century Therapeutics, Inc. | -146.54 Million USD | 96.078% |
| Kura Oncology, Inc. | -165.8 Million USD | 96.533% |
| TScan Therapeutics, Inc. | -93.45 Million USD | 93.85% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | 30.904% |
| Ocean Biomedical, Inc. | -2.48 Million USD | -131.624% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | 11.35% |
| Autolus Therapeutics plc | -195.02 Million USD | 97.053% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 93.21% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | 92.197% |
| Eterna Therapeutics Inc. | -21.13 Million USD | 72.803% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | 97.468% |
| GRI Bio, Inc. | -11.38 Million USD | 49.521% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -27.291% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | 95.619% |
| IGM Biosciences, Inc. | -263.46 Million USD | 97.818% |
| INmune Bio, Inc. | -29.74 Million USD | 80.673% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 94.804% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 84.903% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 64.028% |
| Entero Therapeutics, Inc. | -15.77 Million USD | 63.552% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | 90.592% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | 94.654% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 97.917% |
| Coherus BioSciences, Inc. | -203.19 Million USD | 97.171% |
| Verastem, Inc. | -92.08 Million USD | 93.758% |
| Abeona Therapeutics Inc. | -47.13 Million USD | 87.805% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | 96.879% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | 95.144% |
| Histogen Inc. | -10.64 Million USD | 45.992% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | 62.848% |
| Surrozen, Inc. | -45.78 Million USD | 87.444% |
| Organovo Holdings, Inc. | -15.08 Million USD | 61.898% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -12.924% |
| Ovid Therapeutics Inc. | -59.28 Million USD | 90.304% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 88.794% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | 77.262% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | 24.693% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | 96.644% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | 88.136% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | 92.65% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | 62.235% |
| Apollomics, Inc. | -54.83 Million USD | 89.517% |
| Amarin Corporation plc | -67.58 Million USD | 91.495% |
| Mesoblast Limited | -58.79 Million USD | 90.223% |
| Turnstone Biologics Corp. | -59.03 Million USD | 90.263% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | 96.527% |
| Synaptogenix, Inc. | -8.31 Million USD | 30.861% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | 60.592% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | 93.731% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -19.965% |
| Monopar Therapeutics Inc. | -8.83 Million USD | 34.912% |
| Exelixis, Inc. | 170.88 Million USD | 103.364% |
| Better Therapeutics, Inc. | -38.26 Million USD | 84.977% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | 96.293% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 98.888% |
| NLS Pharmaceutics AG | -11.8 Million USD | 51.317% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | 28.523% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 80.835% |
| Gritstone bio, Inc. | -154.63 Million USD | 96.283% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 91.653% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | 66.431% |
| Avid Bioservices, Inc. | -18.67 Million USD | 69.225% |
| Insmed Incorporated | -709.62 Million USD | 99.19% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | 63.364% |
| MediWound Ltd. | -15.29 Million USD | 62.406% |
| OmniAb, Inc. | -69.41 Million USD | 91.72% |
| Alector, Inc. | -151.74 Million USD | 96.212% |
| Seres Therapeutics, Inc. | -107.98 Million USD | 94.677% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 88.977% |
| Zai Lab Limited | -366.57 Million USD | 98.432% |
| Revance Therapeutics, Inc. | -316.77 Million USD | 98.185% |
| Aura Biosciences, Inc. | -84.99 Million USD | 93.237% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | 97.659% |
| Immunic, Inc. | -99.22 Million USD | 94.207% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | 95.985% |
| Veracyte, Inc. | -85.79 Million USD | 93.3% |
| InMed Pharmaceuticals Inc. | - USD | Infinity% |
| FibroGen, Inc. | -281.81 Million USD | 97.96% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 59.549% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | 16.549% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | 69.413% |
| Jazz Pharmaceuticals plc | 578.58 Million USD | 100.993% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | 77.417% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | 114.814% |
| TG Therapeutics, Inc. | 20.63 Million USD | 127.859% |
| Galecto, Inc. | -39.9 Million USD | 85.596% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 86.338% |
| Fortrea Holdings Inc. | 63.1 Million USD | 109.109% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | 95.907% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | 80.095% |
| XBiotech Inc. | -37.51 Million USD | 84.676% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 91.653% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | 91.436% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | 94.673% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 77.61% |
| Theravance Biopharma, Inc. | -53.29 Million USD | 89.214% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 98.99% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | 92.677% |
| Vaxxinity, Inc. | -58.28 Million USD | 90.138% |
| BioCryst Pharmaceuticals, Inc. | -103.7 Million USD | 94.457% |
| Gain Therapeutics, Inc. | -22.25 Million USD | 74.17% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | 93.348% |
| NexImmune, Inc. | -29.19 Million USD | 80.31% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | -2.277% |
| Marker Therapeutics, Inc. | -14.58 Million USD | 60.579% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 100.142% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | 77.422% |
| Scopus BioPharma Inc. | -11.71 Million USD | 50.934% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | 95.476% |
| Ainos, Inc. | -13.2 Million USD | 56.475% |
| Pluri Inc. | -22.15 Million USD | 74.059% |
| Prothena Corporation plc | -191.03 Million USD | 96.991% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | 95.836% |
| Celularity Inc. | -192.28 Million USD | 97.011% |
| Rallybio Corporation | -78.93 Million USD | 92.718% |
| Cue Biopharma, Inc. | -52.14 Million USD | 88.978% |
| MeiraGTx Holdings plc | -137.06 Million USD | 95.806% |
| Omeros Corporation | -164.53 Million USD | 96.506% |
| Humacyte, Inc. | -100.04 Million USD | 94.255% |
| Immunocore Holdings plc | -59.64 Million USD | 90.363% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | 69.028% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | 76.522% |
| Blueprint Medicines Corporation | -486.27 Million USD | 98.818% |
| CalciMedica, Inc. | -21.87 Million USD | 73.723% |
| Cabaletta Bio, Inc. | -74.66 Million USD | 92.301% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | 95.628% |
| Scholar Rock Holding Corporation | -171.29 Million USD | 96.644% |
| Sana Biotechnology, Inc. | -326.9 Million USD | 98.242% |
| Pulmatrix, Inc. | -14.74 Million USD | 61.004% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | 83.919% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | 93.532% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 98.884% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | 91.491% |
| Cytokinetics, Incorporated | -496.2 Million USD | 98.842% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 83.3% |
| Nutriband Inc. | -4.87 Million USD | -17.984% |
| Protara Therapeutics, Inc. | -43.61 Million USD | 86.82% |
| Vor Biopharma Inc. | -126.03 Million USD | 95.439% |
| Roivant Sciences Ltd. | 4.24 Billion USD | 100.136% |
| Evogene Ltd. | -26.39 Million USD | 78.22% |
| ProKidney Corp. | -151.52 Million USD | 96.206% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 91.093% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | 25.274% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 99.054% |
| CorMedix Inc. | -48.95 Million USD | 88.259% |
| BioLineRx Ltd. | -49.69 Million USD | 88.433% |
| Tango Therapeutics, Inc. | -114.17 Million USD | 94.965% |
| Galectin Therapeutics Inc. | -38.07 Million USD | 84.902% |
| Atai Life Sciences N.V. | -125.47 Million USD | 95.419% |
| Renovaro Biosciences Inc. | -81.63 Million USD | 92.959% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | 92.939% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | 97.691% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 81.301% |
| MediciNova, Inc. | -9.9 Million USD | 41.94% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | 95.451% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 20.634% |
| GeoVax Labs, Inc. | -26.74 Million USD | 78.506% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 97.521% |
| Biomea Fusion, Inc. | -126.13 Million USD | 95.443% |
| PTC Therapeutics, Inc. | -349.4 Million USD | 98.355% |
| Mereo BioPharma Group plc | -28.41 Million USD | 79.772% |
| Cullinan Oncology, Inc. | -191.08 Million USD | 96.992% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | 97.5% |
| Absci Corporation | -115.51 Million USD | 95.024% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 79.164% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | 94.907% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | 97.626% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | 77.187% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | 97.236% |
| Allakos Inc. | -196.05 Million USD | 97.068% |
| Imunon, Inc. | -21.03 Million USD | 72.668% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | 94.806% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 105.358% |
| BioAtla, Inc. | -129.68 Million USD | 95.568% |
| NLS Pharmaceutics AG | -11.8 Million USD | 51.317% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | 63.719% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | 98.246% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | 86.235% |
| XOMA Corporation | -41.84 Million USD | 86.264% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | 94.538% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 95.269% |
| aTyr Pharma, Inc. | -54.91 Million USD | 89.534% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | 93.425% |
| Akero Therapeutics, Inc. | -172.87 Million USD | 96.675% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 97.741% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | 73.222% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | 30.01% |
| Akari Therapeutics, Plc | -16.8 Million USD | 65.797% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -64901.227% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 101.703% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 12.028% |
| UroGen Pharma Ltd. | -65.53 Million USD | 91.229% |
| Sutro Biopharma, Inc. | -89.27 Million USD | 93.562% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 20.858% |
| Orgenesis Inc. | -53.63 Million USD | 89.283% |
| Entera Bio Ltd. | -8.89 Million USD | 35.349% |
| GH Research PLC | -41.22 Million USD | 86.056% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | 77.641% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | 93.079% |
| Xencor, Inc. | -138.63 Million USD | 95.854% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | -11.514% |
| Replimune Group, Inc. | -234.77 Million USD | 97.552% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | 73.254% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | 58.801% |
| Lexaria Bioscience Corp. | -6.53 Million USD | 12.028% |
| Portage Biotech Inc. | -18.25 Million USD | 68.509% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | 20.634% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | 94.524% |
| OncoCyte Corporation | -25.13 Million USD | 77.132% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | 49.154% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | 49.829% |
| Purple Biotech Ltd. | 22.27 Million USD | 125.81% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | 23.481% |
| scPharmaceuticals Inc. | -55.39 Million USD | 89.624% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | 69.583% |
| HilleVax, Inc. | -133.34 Million USD | 95.689% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | 52.294% |
| Tharimmune, Inc. | -9.45 Million USD | 39.207% |
| Genprex, Inc. | -31.07 Million USD | 81.503% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | 96.946% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | 81.681% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | -651.383% |
| Virios Therapeutics, Inc. | -5.44 Million USD | -5.529% |
| OKYO Pharma Limited | -15.74 Thousand USD | -36396.359% |
| Savara Inc. | -60 Million USD | 90.421% |
| Curis, Inc. | -48.33 Million USD | 88.107% |
| Daré Bioscience, Inc. | -30.83 Million USD | 81.362% |
| Carmell Therapeutics Corporation | -5.21 Million USD | -10.174% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | 21.01% |
| Achieve Life Sciences, Inc. | -27.25 Million USD | 78.906% |
| BeiGene, Ltd. | -1.2 Billion USD | 99.524% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | 71.172% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 98.82% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | 93.862% |
| Erasca, Inc. | -141.52 Million USD | 95.938% |
| bluebird bio, Inc. | -244.26 Million USD | 97.647% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -26.974% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 102.956% |
| DBV Technologies S.A. | -76.43 Million USD | 92.479% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -26.974% |
| Moderna, Inc. | -4.23 Billion USD | 99.864% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 86.51% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | 9.621% |
| Molecular Templates, Inc. | -10.46 Million USD | 45.079% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | 91.451% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 98.474% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | 95.989% |
| Spruce Biosciences, Inc. | -51.99 Million USD | 88.945% |
| Celldex Therapeutics, Inc. | -154.54 Million USD | 96.281% |
| Cogent Biosciences, Inc. | -208.13 Million USD | 97.238% |
| MacroGenics, Inc. | -168.24 Million USD | 96.583% |
| RenovoRx, Inc. | -11.39 Million USD | 49.561% |
| Adicet Bio, Inc. | -152.03 Million USD | 96.219% |
| Prime Medicine, Inc. | -191.29 Million USD | 96.995% |
| Aditxt, Inc. | -26.06 Million USD | 77.945% |
| Adagene Inc. | -23.71 Million USD | 75.767% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 21.368% |
| Quantum-Si incorporated | -111.17 Million USD | 94.83% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | 81.837% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 60.57% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | 104.711% |
| SciSparc Ltd. | -5.77 Million USD | 0.432% |
| Vericel Corporation | -6.46 Million USD | 11.076% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 33.599% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | 75.138% |
| Generation Bio Co. | -138.56 Million USD | 95.852% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 93.077% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | 93.352% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | 97.616% |
| Invivyd, Inc. | -207.78 Million USD | 97.234% |
| Relay Therapeutics, Inc. | -373 Million USD | 98.459% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | 38.71% |
| Spero Therapeutics, Inc. | 21.48 Million USD | 126.759% |
| Artelo Biosciences, Inc. | -10.28 Million USD | 44.123% |
| 2seventy bio, Inc. | -216.7 Million USD | 97.347% |
| ADMA Biologics, Inc. | 21.63 Million USD | 126.572% |
| Clene Inc. | -40.54 Million USD | 85.821% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | 76.127% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | 89.51% |
| GeoVax Labs, Inc. | -26.74 Million USD | 78.506% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | 98.358% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | 84.351% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | 135.753% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | 94.457% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 83.095% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | 96.624% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 99.16% |
| Evaxion Biotech A/S | -22.19 Million USD | 74.104% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | 93.023% |
| Verve Therapeutics, Inc. | -223.12 Million USD | 97.424% |
| Trevena, Inc. | -35.28 Million USD | 83.711% |
| Surrozen, Inc. | -45.78 Million USD | 87.444% |
| Tyra Biosciences, Inc. | -79.94 Million USD | 92.81% |
| Cingulate Inc. | -22.75 Million USD | 74.744% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | 176.723% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 87.131% |
| Tenax Therapeutics, Inc. | -8.23 Million USD | 30.19% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | 94.395% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | 92.167% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | 90.74% |
| Clearmind Medicine Inc. | -8.74 Million USD | 34.243% |
| Kronos Bio, Inc. | -121.83 Million USD | 95.282% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | 92.456% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -95.98% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 94.299% |
| Statera Biopharma, Inc. | -98.34 Million USD | 94.155% |
| ImmunityBio, Inc. | -362.25 Million USD | 98.413% |
| Korro Bio, Inc. | -84.53 Million USD | 93.2% |
| Kineta, Inc. | -15.72 Million USD | 63.442% |
| BioVie Inc. | -32.17 Million USD | 82.138% |
| Codexis, Inc. | -68.06 Million USD | 91.556% |
| Celularity Inc. | -192.28 Million USD | 97.011% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | 97.418% |
| Celcuity Inc. | -66.23 Million USD | 91.321% |
| Virax Biolabs Group Limited | -6.49 Million USD | 11.52% |
| Cibus, Inc. | -318.88 Million USD | 98.197% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | 86.632% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 83.016% |
| IN8bio, Inc. | -30.33 Million USD | 81.053% |
| Kodiak Sciences Inc. | -277.32 Million USD | 97.927% |
| Annexon, Inc. | -143.72 Million USD | 96.001% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | 95.357% |
| Assembly Biosciences, Inc. | -64.64 Million USD | 91.108% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | 75.482% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 98.375% |
| Eyenovia, Inc. | -25.4 Million USD | 77.376% |
| Puma Biotechnology, Inc. | 32.64 Million USD | 117.611% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -3.346% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | 92.736% |
| Arcellx, Inc. | -89.88 Million USD | 93.605% |
| Cardiff Oncology, Inc. | -45.41 Million USD | 87.342% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | 95.811% |
| Regulus Therapeutics Inc. | -31.1 Million USD | 81.523% |
| Moolec Science SA | -6.65 Million USD | 13.612% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | 90.598% |
| Geron Corporation | -193.94 Million USD | 97.036% |
| LAVA Therapeutics N.V. | -43.25 Million USD | 86.711% |
| Royalty Pharma plc | 1.49 Billion USD | 100.385% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | 96.499% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | 38.377% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | 73.747% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | 96.638% |
| Humacyte, Inc. | -100.04 Million USD | 94.255% |
| Structure Therapeutics Inc. | -102.77 Million USD | 94.407% |
| 89bio, Inc. | -151.2 Million USD | 96.198% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | 92.827% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | 60.467% |
| Genelux Corporation | -24.16 Million USD | 76.213% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | 83.056% |
| Lexicon Pharmaceuticals, Inc. | -171.75 Million USD | 96.653% |
| Notable Labs, Ltd. | -14.65 Million USD | 60.783% |
| Liquidia Corporation | -73.38 Million USD | 92.167% |
| Mustang Bio, Inc. | -50.72 Million USD | 88.668% |
| Immunovant, Inc. | -282.7 Million USD | 97.967% |
| Quantum-Si incorporated | -111.17 Million USD | 94.83% |
| Arbutus Biopharma Corporation | -78.1 Million USD | 92.64% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | 72.972% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 94.365% |
| Acasti Pharma Inc. | -11.31 Million USD | 49.186% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | 74.922% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 64.028% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | 97.315% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | -56.663% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 63.817% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | 80.286% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | 86.11% |
| PepGen Inc. | -84.76 Million USD | 93.219% |
| Moleculin Biotech, Inc. | -29.63 Million USD | 80.601% |
| United Therapeutics Corporation | 1.18 Billion USD | 100.485% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 74.896% |
| Solid Biosciences Inc. | -104.31 Million USD | 94.49% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | 82.48% |
| Immuneering Corporation | -58.41 Million USD | 90.16% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -12.924% |
| Silo Pharma, Inc. | -3.85 Million USD | -49.084% |
| Belite Bio, Inc | -31.66 Million USD | 81.849% |
| XOMA Corporation | -41.84 Million USD | 86.264% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | 91.487% |
| Bionomics Limited | -17.89 Billion USD | 99.968% |
| Apogee Therapeutics, Inc. | -93 Million USD | 93.819% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 116.11% |
| uniQure N.V. | -282.87 Million USD | 97.968% |
| Cassava Sciences, Inc. | -105.95 Million USD | 94.575% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | 21.368% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 95.561% |
| Forte Biosciences, Inc. | -32.48 Million USD | 82.306% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | 30.819% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | 80.445% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -3.346% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 59.549% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | 35.335% |
| Altimmune, Inc. | -95.92 Million USD | 94.008% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 92.179% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 116.11% |
| Compugen Ltd. | -12.99 Million USD | 55.757% |
| Peak Bio, Inc. | -1356.23 USD | -423727.669% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | 88.412% |
| Benitec Biopharma Inc. | -22.49 Million USD | 74.442% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 97.628% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | 80.676% |
| Zura Bio Limited | -62.63 Million USD | 90.823% |
| PolyPid Ltd. | -22.86 Million USD | 74.863% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | 64.684% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | 80.676% |
| Instil Bio, Inc. | -159.16 Million USD | 96.389% |
| argenx SE | -425.04 Million USD | 98.648% |
| Immunome, Inc. | -109.53 Million USD | 94.752% |
| Compass Therapeutics, Inc. | -50.36 Million USD | 88.587% |
| Verona Pharma plc | -67.83 Million USD | 91.526% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | 77.943% |
| Shattuck Labs, Inc. | -91.95 Million USD | 93.749% |
| CervoMed Inc. | -7.81 Million USD | 26.428% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | 92.138% |
| Plus Therapeutics, Inc. | -13.32 Million USD | 56.85% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 88.068% |
| Moolec Science SA | -6.65 Million USD | 13.612% |
| Enveric Biosciences, Inc. | -16.44 Million USD | 65.054% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | 95.749% |
| AnaptysBio, Inc. | -164.41 Million USD | 96.504% |
| Design Therapeutics, Inc. | -78.19 Million USD | 92.649% |
| Leap Therapeutics, Inc. | -87.04 Million USD | 93.396% |
| NeurAxis, Inc. | -6.66 Million USD | 13.751% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | 85.807% |
| Lumos Pharma, Inc. | -36.61 Million USD | 84.301% |
| Achilles Therapeutics plc | -75.25 Million USD | 92.362% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | 77.943% |
| 180 Life Sciences Corp. | -13.47 Million USD | 57.351% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | 211.477% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -95.98% |
| Nutriband Inc. | -4.87 Million USD | -17.984% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | 94.811% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | 89.634% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | 88.693% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | 91.304% |
| MoonLake Immunotherapeutics | -54.12 Million USD | 89.38% |
| Palisade Bio, Inc. | -13.07 Million USD | 56.021% |
| Tourmaline Bio, Inc. | -45.4 Million USD | 87.342% |
| Beam Therapeutics Inc. | -176.48 Million USD | 96.743% |
| Neurogene Inc. | -55.58 Million USD | 89.659% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | 94.734% |
| AEON Biopharma, Inc. | -48.42 Million USD | 88.131% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | 94.056% |
| Sesen Bio, Inc. | -25.9 Million USD | 77.814% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | 93.118% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | 54.333% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 98.752% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | 92.065% |
| Athira Pharma, Inc. | -125.46 Million USD | 95.419% |
| Vaccinex, Inc. | -22.88 Million USD | 74.883% |
| HCW Biologics Inc. | -25.71 Million USD | 77.649% |
| XOMA Corporation | -41.84 Million USD | 86.264% |
| Nektar Therapeutics | -137.42 Million USD | 95.817% |
| Arvinas, Inc. | -401.5 Million USD | 98.568% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -64901.227% |
| Merus N.V. | -156.54 Million USD | 96.328% |
| Omega Therapeutics, Inc. | -100.26 Million USD | 94.267% |
| Quince Therapeutics, Inc. | -34.62 Million USD | 83.397% |
| Rezolute, Inc. | -70.42 Million USD | 91.838% |
| Clene Inc. | -40.54 Million USD | 85.821% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | 64.905% |
| BeyondSpring Inc. | -23.11 Million USD | 75.132% |
| Synlogic, Inc. | -55.16 Million USD | 89.579% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | 67.94% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 46.895% |
| Peak Bio, Inc. | -1356.23 USD | -423727.669% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | 85.808% |
| Krystal Biotech, Inc. | -109.72 Million USD | 94.761% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | 95.563% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | 98.324% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | -21.115% |
| MannKind Corporation | 8.67 Million USD | 166.237% |
| Ikena Oncology, Inc. | -75.41 Million USD | 92.378% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | 40.416% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | 91.45% |
| Gossamer Bio, Inc. | -183.75 Million USD | 96.872% |
| CohBar, Inc. | -12.38 Million USD | 53.601% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | 88.668% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 79.164% |
| Legend Biotech Corporation | -439.48 Million USD | 98.692% |
| Mural Oncology plc | -194.63 Million USD | 97.047% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 91.439% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 64.398% |
| Disc Medicine, Inc. | -91.12 Million USD | 93.692% |
| Champions Oncology, Inc. | -7.35 Million USD | 21.859% |
| REGENXBIO Inc. | -268.12 Million USD | 97.856% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | 46.371% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 89.691% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | 85.246% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | 94.974% |
| Vaxart, Inc. | -83.34 Million USD | 93.103% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | 32.534% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | 86.568% |
| Cellectis S.A. | -106.62 Million USD | 94.609% |
| Longeveron Inc. | -21.02 Million USD | 72.666% |
| Repare Therapeutics Inc. | -116.22 Million USD | 95.054% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 97.854% |
| Inozyme Pharma, Inc. | -75.64 Million USD | 92.401% |
| Revolution Medicines, Inc. | -487.18 Million USD | 98.82% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | 13.589% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | 86.923% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 92.294% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | 91.745% |
| Anixa Biosciences, Inc. | -11.01 Million USD | 47.797% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 100.133% |
| Denali Therapeutics Inc. | -196.69 Million USD | 97.078% |
| Revelation Biosciences, Inc. | -8.65 Million USD | 33.599% |
| Veru Inc. | -93.78 Million USD | 93.871% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | 75.361% |
| Cingulate Inc. | -22.75 Million USD | 74.744% |
| Passage Bio, Inc. | -108.38 Million USD | 94.697% |
| Context Therapeutics Inc. | -25.07 Million USD | 77.074% |
| Exicure, Inc. | -14.99 Million USD | 61.669% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 97.211% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | 85.841% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | 40.845% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | 96.882% |
| Nuvalent, Inc. | -149.49 Million USD | 96.155% |
| ABVC BioPharma, Inc. | -8.21 Million USD | 30.042% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | 93.522% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | 72.33% |
| OmniAb, Inc. | -69.41 Million USD | 91.72% |
| Anew Medical, Inc. | -1.3 Million USD | -341.874% |
| Fennec Pharmaceuticals Inc. | -12.77 Million USD | 54.991% |
| Lipocine Inc. | -17.93 Million USD | 67.943% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | 91.61% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | 92.452% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 84.903% |
| G1 Therapeutics, Inc. | -39.52 Million USD | 85.458% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | 74.321% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 99.009% |
| Ocugen, Inc. | -65.53 Million USD | 91.228% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | 93.876% |
| Q32 Bio Inc. | -92.1 Million USD | 93.759% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | 73.189% |
| Alumis Inc. Common Stock | -158.17 Million USD | 96.366% |
| Equillium, Inc. | -14.52 Million USD | 60.418% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | 90.789% |
| Coya Therapeutics, Inc. | -7.9 Million USD | 27.27% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 69.531% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 87.757% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 94.701% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | 51.979% |
| Dominari Holdings Inc. | -21.79 Million USD | 73.628% |
| Edesa Biotech, Inc. | -9.22 Million USD | 37.675% |
| vTv Therapeutics Inc. | -25.5 Million USD | 77.46% |
| Bio-Techne Corporation | 206.68 Million USD | 102.781% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 98.532% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | 102.993% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | 95.655% |
| Candel Therapeutics, Inc. | -38.39 Million USD | 85.028% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 96.196% |
| Nkarta, Inc. | -131.65 Million USD | 95.634% |
| BioCardia, Inc. | -11.64 Million USD | 50.635% |
| Iterum Therapeutics plc | -47.46 Million USD | 87.891% |